CPT® Code 0538T

Deleted

Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)

Chimeric antigen receptor T-cell (CAR-T) therapy represents a groundbreaking approach in the field of immunotherapy, utilizing the patient's own white blood cells, specifically lymphocytic T-cells, to combat cancer. This innovative treatment involves a sophisticated process where T-cells are extracted from the patient's blood, typically over a span of one or more days. The extracted T-lymphocytes are then subjected to genetic engineering in a controlled laboratory or manufacturing environment. This is achieved by introducing a disarmed virus that carries genetic material into the T-cells, prompting them to produce chimeric antigen receptors (CARs) on their surfaces. These CARs are crucial as they enable the T-cells to identify and bind to specific protein antigens present on the surface of cancer cells. Once the T-cells are genetically modified to express CARs, they undergo a significant expansion phase, multiplying to reach hundreds of millions of cells. During this manufacturing period, the patient typically receives lymphocytic cell-depleting chemotherapy to prepare their immune system for the subsequent infusion of the engineered T-cells. After the CAR-T cells are fully prepared and the patient is adequately primed, the modified T-cells are infused back into the patient's bloodstream. The CARs on the surface of these engineered T-cells facilitate their recognition and destruction of cancer cells, effectively targeting and eliminating malignant cells. Furthermore, the CAR-T cells are designed to persist in the patient's body for an extended duration, providing ongoing surveillance against potential cancer recurrence.